BIOSE
LIVE

Serial Number

79182715

Owner

BIOSE INDUSTRIE

Attorney

William S. Fultz

Filing Date

Jul 3, 2015

Add to watchlist:

No watchlists yet
View on USPTO

BIOSE Trademark

Serial Number: 79182715 • Registration: 5056931

BIOSE is a trademark filed by BIOSE INDUSTRIE on July 3, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

BIOSE INDUSTRIE (5 trademarks)

Rue des Frères Lumière
Arpajon Sur Cere F-15130 , FR

Entity Type: 99

BIOSE (13 trademarks)

Rue des Frères Lumière

Entity Type: 99

Trademark Details

Filing Date

July 3, 2015

Registration Date

October 11, 2016

Published for Opposition

July 26, 2016

Goods & Services

[ Pharmaceutical products made with the microbiota, namely, bacteria, probiotics and tribiotics for treating gynecological disorders, intestinal disorders, gastroenterological disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat, allergies; chemical or biological pharmaceutical preparations for pharmaceutical, medical and sanitary purposes, namely, microbiota, bacteria, probiotics and tribiotics for treating gynecological disorders, intestinal disorders, gastroenterological disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat, allergies; sanitary and medical preparations, namely, bacteria for use in the composition of biological pharmaceuticals for treating gynecological disorders, intestinal disorders, gastroenterological disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat, allergies; biological or chemical preparations for pharmaceutical, medical use, toilet, namely, probiotics, tribiotics in capsules, capsules and sachets for treating or preventing the gastroenterological disease, gyncological, ear, nose and throat, dermatological, allergic, immune or inflammatory, diseases associated with an imbalance in the vaginal or intestinal flora, flatulence, diarrhea, abdominal pain, spasms, or for improving regulation of intestinal transit; vaginal capsules for treating gynecological diseases; preparations for medical use, namely, antifungals, antimycotics, antiflatulent agents, antidiarrheic agents, antispasmodics, antiinflammatories or antibiotics; disinfectants for hygiene care of patients suffering from gastroenterological diseases, imbalance of the intestinal flora, gynecological diseases, imbalance of the vaginal flora; nutritional supplements, namely, food beverages, bars and meal replacement substances adapted for medical use, dietetic purposes, treating or preventing gynecological disorders, gastroenterological, intestinal disorders linked to imbalances in the intestinal flora, vaginal flora, dermatological diseases, immune, auto-immune and inflammatory, diseases of the ear, nose and throat; nutritional supplements, namely, meal replacement foods, beverages, bars made from a combination of probiotics, minerals and/or vitamins; vitamin preparations, namely, vitamin supplements; medical preparations for slimming; mineral food supplements ]

[ Arranging and conducting of educational colloquiums, conferences, seminars and events for scientific purposes in the field of microbiota, of probiotics as pharmaceutical preparations, of the probiotics industry, of good practice in the field of microbiota, of probiotics, of changes to regulations relating to probiotics and microbiota ]

Laboratory services for the provision of scientific analysis and research services, medical, pharmaceutical, pharmacological, bacteriological, chemical and microbiological, design and production of pharmaceutical preparations, probiotics, tribiotics for others; consulting in production of pharmaceutical preparations; quality control; testing in laboratory; services for assessing the efficiency of pharmaceuticals; auditing and auditing pharmaceutical manufacturing processes; packaging design services; kitchen design of preventive quality assurance and quality control relating to the manufacture of pharmaceutical preparations; auditing and testing standards and practices in the field of the manufacture of probiotics, tribiotics, ensure compliance with governmental regulations and industrial practices, practices quality control and quality assurance; conducting pharmaceutical research projects and technical project studies; engineering; provision of information and data relating to medical and scientific research in the field of pharmaceuticals, probiotics, and clinical trials relating to scientific research and development; provision and exchange of knowledge, industrial know-how and data relating to scientific research and development; provision and exchange of information and data exchange between scientists, manufacturers and health authorities relating to pharmaceutical regulatory affairs and the application thereof to probiotics; expertise services and technical advice in the field of scientific research for medical and pharmaceutical purposes, in the field of probiotics; development and maintenance of data banks and databases; extraction and retrieval of information and data mining; managing of working groups bringing together scientists and manufacturers to resolve problems in connection with probiotics; research and drafting of information provided by scientific research in the field of medical research, pharmaceutical, pharmacological in regulatory affairs in the field of probiotics

Filing History

TEAS SECTION 71 RECEIVED
May 5, 2026 ES71
NEW REPRESENTATIVE AT IB RECEIVED
Jan 22, 2026 NREP
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Oct 11, 2025 REM4
INTERNATIONAL REGISTRATION RENEWED
Jul 24, 2025 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Oct 31, 2023 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 23, 2023 INPS
INVALIDATION PROCESSED
Sep 23, 2023 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 13, 2023 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Jan 13, 2023 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Jan 13, 2023 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 10, 2023 APRE
TEAS SECTION 71 RECEIVED
Jul 1, 2022 ES71
CHANGE OF OWNER RECEIVED FROM IB
Sep 11, 2020 CHLD
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Mar 13, 2017 CORN
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 3, 2017 FINO
CORRECTION TRANSACTION RECEIVED FROM IB
Feb 17, 2017 CRCV
FINAL DISPOSITION NOTICE SENT TO IB
Feb 13, 2017 FICS
FINAL DISPOSITION PROCESSED
Feb 13, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 11, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 11, 2016 R.PR
PUBLISHED FOR OPPOSITION
Jul 26, 2016 PUBO
NOTICE OF PUBLICATION
Jul 6, 2016 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 20, 2016 PREV
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 16, 2016 ADCH
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2016 CRFA
ASSIGNED TO LIE
May 27, 2016 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 17, 2016 TROA
REFUSAL PROCESSED BY IB
Mar 26, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2016 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 4, 2016 RFCR
NON-FINAL ACTION WRITTEN
Mar 3, 2016 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 1, 2016 MAFR
ASSIGNED TO EXAMINER
Feb 25, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 25, 2016 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Feb 24, 2016 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 23, 2016 REPR